2 January 2024FeaturesBig PharmaManita Rawat and Alexander Stein

2024 forecast: AI, patent eligibility and Fintiv

A few key items related to patents in the US are at the forefront of shaping our patent laws in 2024.

Already registered?

For multi-user price options, or to check if your company has an existing subscription that we can add you to for FREE, please email Atif Choudhury at achoudhury@lifesciencesipreview.com

More on this story

Big Pharma

What’s at stake in Australia’s biggest pharma patent appeal in years?

1 July 2026 The Otsuka v Sun Pharma appeal could redefine which pharmaceutical patents qualify for patent term extensions, with major implications for innovator companies, generic manufacturers and the future of market exclusivity in Australia.

Big Pharma

US life sciences damages averaged $33.5m between 2019-2025

18 June 2026 Despite a slowdown in US patent litigation, life sciences remains one of the most active sectors—but companies are using a wider than ever IP toolkit, says a new study.

Big Pharma

Novo Nordisk and OpenAI strike AI deal to boost drug discovery

15 April 2026 The Danish pharma giant is turning to artificial intelligence as it faces patent expiry, falling shares and intensifying competition from Eli Lilly.

More features

Vinson & Elkins grows West Coast patent and trade secrets bench

What’s at stake in Australia’s biggest pharma patent appeal in years?

Will Mounjaro and Zepbound get their first US generic rival?

King & Spalding continues hiring spree from pre-merged Winston

Pfizer’s US Paxlovid patent fight turns on a single error

Novo secures website blocking to tackle fake weight-loss drugs

GLP-1 patents and Africa: The COVID-19 lessons we still have not learned

Cooley Asia transactions duo make rival firm move

2024 forecast: AI, patent eligibility and Fintiv

More on this story

Editor's picks

Editor's picks

More features